Reporting the results of a first-of-its-kind phase 1 clinical trial to test the effectiveness of a new class of drugs to augment standard chemotherapy, a team led by Fred Hutchinson Cancer Research Center scientists found that giving patients high doses of Vorinostat in combination with another round of commonly used second-line drugs resulted in a ... (more)
http://www.sciencedaily.com/releases/2013/02/130204114254.htm?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine%2Fdiseases_and_conditions+%28ScienceDaily%3A+Health+%26+Medicine+News+--+Diseases+and+Conditions%29
http://www.sciencedaily.com/releases/2013/02/130204114254.htm?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+sciencedaily%2Fhealth_medicine%2Fdiseases_and_conditions+%28ScienceDaily%3A+Health+%26+Medicine+News+--+Diseases+and+Conditions%29
No comments:
Post a Comment